Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Paradigm Genetics Sees Revenue Upswing, Increased Losses

SAN FRANCISCO, May 1 - Paradigm Genetics today posted an 8 percent increase in revenue and widened net losses in its first quarter.


Total revenue for the first quarter ended March 31 came in at $5.9 million compared with $5.4 million one year ago. The company said the revenue rise was from the sale of herbicide assays developed in collaboration with Bayer.


Net loss for the quarter increased to $5.2 million, or $.16 per common share, compared with $4 million, or $.15 a share, for the year-ago period, according to the company.


R&D spending increased to $8.1 million compared to $6.4 million for the first quarter in 2001.


Paradigm Genetics said it had roughly $8.3 million in cash, cash equivalents, and short-term investments as of March 31.


Click here for more information.


The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.